



Antimicrobial Therapy in Intensive Care Unit

Guest Editors:

Dr. Elizabeth Paramythiotou

2nd Department of Intensive
Care, School of Medicine,
National and Kapodistrian
University of Athens, 'Attikon'
Hospital, Athens, Greece

Prof. Dr. Christina Routsis

Medical School, National and
Kapodistrian University of
Athens, ICU Evangelismos
Hospital, Athens, Greece

Dr. Antoine Andremont

Faculté de Médecine, Université
de Paris, Paris, France

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editors

Antimicrobial therapy in the intensive care unit (ICU) is one of the greatest challenges of contemporary medicine. The arising therapeutic problems are more prominent in the ICU setting, where patients are more vulnerable. Newer pandemics such as COVID-19 and the resulting overuse of antibiotics are adding to the existing burden. For all the abovementioned reasons, this Special Issue seeks manuscript submissions that further our understanding on antimicrobial use in intensive care units. Authors are invited to submit manuscripts of original preclinical and clinical research as well as narrative and systematic reviews/meta-analysis within their area of interest including (but not limited) to the topics highlighted below:

- Antibiotic optimization, including PK/PD;
- Novel antibiotics, antifungals, and antivirals, branded or emerging;
- Alternative to antibiotics approaches to prevent or tackle infections, such as antibodies, bacteriophages, vaccines, immunotherapeutics;
- De-escalation;
- Antibiotic stewardship, including strategies to combat antibiotic overuse and combat resistance;
- Antibiotic access, antibiotic innovation;
- Microbiota.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)